US11617753B2 - Methods of treating and inhibiting Ebola virus infection - Google Patents
Methods of treating and inhibiting Ebola virus infection Download PDFInfo
- Publication number
- US11617753B2 US11617753B2 US16/348,867 US201716348867A US11617753B2 US 11617753 B2 US11617753 B2 US 11617753B2 US 201716348867 A US201716348867 A US 201716348867A US 11617753 B2 US11617753 B2 US 11617753B2
- Authority
- US
- United States
- Prior art keywords
- ebola virus
- formula
- sangivamycin
- pharmaceutically acceptable
- ebola
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
Definitions
- FIGS. 1 A- 1 D are micrographs depicting the EGFP fluorescence and Hoechst 33342 nuclear DNA stains of wild type Ebola virus and the L117R Ebola virus mutation.
- FIG. 1 A is an image depicting EGFP fluorescence from the VP40 protein tagged with EGFP of the VP40 from wild type Ebola virus.
- FIG. 1 B is the corresponding Hoechst 33342 DNA stain.
- FIGS. 1 A and 1 B indicate the wild type virus can dimerize, hence, form the hexamers which led to the formation of the viral capsid.
- FIGS. 1 C and 1 D demonstrate that the L117R mutation prevents dimerization resulting in the inability of the mutated virus to form virus-like particles (VLPs) on the plasma membrane, i.e., the fluorescent rings around the edges of cells.
- VLPs virus-like particles
- FIG. 2 A- 2 F are micrographs of Ebola virus treated with 2.34 nM, 9.38 nM and 37.5 nM sangivamycin, respectively.
- FIGS. 2 A- 2 F indicate the wild type virus can dimerized, hence, form the hexamers which led to the formation of the viral capsid.
- FIGS. 2 G- 2 J show a shift in membrane association as depicted in a L117R Ebola virus mutation shown in FIG. 1 C at 150 nM ( FIG. 2 G ) and 600 nM ( FIG. 21 ), revealing that at concentrations above 37.5 nM sangivamycin prevents VLP formation in the cell.
- FIG. 3 is a series of histograms that represent the reduced fluorescence (expressed as % of solvent control signal) of EGFP tagged VP40 proteins expressed in cells treated with the disclosed compounds at varying concentrations.
- A-F the doses are in each histogram from left to right 30 ⁇ M, 15 ⁇ M, 7.5 ⁇ M, 3.75 ⁇ M, 1.88 ⁇ M, 0.94 ⁇ M, and 0.46 ⁇ M respectively.
- Histogram A represents sangivamycin
- B represents sangivamycin HCl salt
- F represents thiosangivamycin.
- Histograms C-E represent Formulae IIIb-IIId disclosed herein.
- FIG. 4 lanes 1, 2 and 3 represent 3 ⁇ L, 6 ⁇ L and 12 ⁇ L of VLP isolated from wild type VP40 expressing cells.
- FIG. 4 lane 4 represents 12 ⁇ L of VLP isolated from mutated L117R VP40 expressing cells, indicating a lack of VLP formation.
- FIG. 5 A-D depicts VLP isolated from A) DMSO control, B) 5 nM sangivamycin, C) 50 nM sangivamycin, and D) 500 nM sangivamycin with lanes 1, 2 and 3 again showing 3 ⁇ L, 6 ⁇ L and 12 ⁇ L of VLP.
- FIGS. 5 A and 5 B show similar amounts of VLP, while FIG. 5 C shows a clear reduction in VLP at 50 nM sangivamycin.
- FIG. 5 D shows a drastic reduction in VLP at 500 nM sangivamycin with VLP only faintly detected at 12 ⁇ L in lane 3.
- FIG. 6 depicts the percent inhibition ( ⁇ ) and percent cytotoxicity ( ⁇ ) of sangivamycin in a minigenome assay which measures inhibition of RNA transcription and replication through the Ebola L polymerase.
- a luciferase reporter was used to obtain % inhibition, whereas a tetrazolium salt-based cell viability assay (WST) was used to measure the relative cytotoxicity.
- WST tetrazolium salt-based cell viability assay
- FIGS. 7 A- 7 F are graphs summarizing in vitro cell-based antiviral assays. The percent inhibition that the test compounds displayed is indicated by ( ⁇ ), whereas the percent toxicity is indicated by ( ⁇ ). These assays were used to evaluate the antiviral capability of the disclosed compounds against a fully-functional Ebola virus.
- Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.
- any embodiment of any of the disclosed methods or compositions can consist of or consist essentially of—rather than comprise/include/contain/have—any of the described steps, elements, and/or features.
- the term “consisting of” or “consisting essentially of” can be substituted for any of the open-ended linking verbs recited above, in order to change the scope of a given claim from what it would otherwise be using the open-ended linking verb.
- any embodiment of any of the disclosed compounds or methods can consist of or consist essentially of—rather than comprise/include/contain/have—any of the described steps, elements, and/or features.
- the term “consisting of” or “consisting essentially of” can be substituted for any of the open-ended linking verbs recited above, in order to change the scope of a given claim from what it would otherwise be using the open-ended linking verb.
- subject refers to a human or an animal that has been diagnosed with one or more strains of Ebola virus or has tested positive for Ebola virus.
- subject also includes humans or animals that have been exposed to Ebola virus but are not symptomatic.
- the terms “treat,” “treating,” “treatment,” and the like refer to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.
- the terms “prevent,” “preventing,” “prevention,” “prophylactic treatment” and the like are encompassed within the term “treating,” and refer to reducing the probability of developing a disorder or condition in a subject, who does not have, but is at risk of or susceptible to developing a disorder or condition.
- pharmaceutically acceptable means physiologically tolerable, for either human or veterinary applications.
- pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
- the pharmaceutically acceptable material is nontoxic to the recipient.
- the carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.
- pharmaceutically acceptable carriers and other components of pharmaceutical compositions see, e.g., Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, 1990.
- Test agents or otherwise “test compounds” as used herein refers to an agent or compound that is to be screened in one or more of the assays described herein.
- Test agents include compounds of a variety of general types including, but not limited to, small organic molecules, known pharmaceuticals, polypeptides; carbohydrates such as oligosaccharides and polysaccharides; polynucleotides; lipids or phospholipids; fatty acids; steroids; or amino acid analogs.
- Test agents can be obtained from libraries, such as natural product libraries and combinatorial libraries. In addition, methods of automating assays are known that permit screening of several thousands of compounds in a short period.
- One aspect of the disclosure comprises, contacting the subject with a therapeutically effective amount of one or more compounds having Formula I:
- X is chosen from O or S; R 1 is chosen from —NH 2 , —NHOH and —NHNH 2 ; and R 2 is chosen from hydrogen and —NHNH 2 ; or a pharmaceutically acceptable salt thereof.
- the disclosed compounds can be used to treat, cure, abate, minimize, control, and/or lessen the effects of Ebola virus in humans and animals.
- the disclosed compounds can also be used to slow the rate of Ebola virus spread in a population.
- the disclosed compounds when administered to a subject in need of treatment can be used to stop the spread of Ebola virus.
- the compounds disclosed herein can be administered as part of a combination therapy with one or more drugs or other pharmaceutical agents.
- the methods comprise administering an effective amount of one or more of the disclosed compounds to a subject diagnosed or exposed to one or more Ebola viruses.
- Ebola viruses include Ivory Coast Ebola virus (ICEBOV), Zaire Ebola virus (ZEBOV), and Sudan Ebola Virus (SEBOV).
- ICEBOV Ivory Coast Ebola virus
- ZEBOV Zaire Ebola virus
- SEBOV Sudan Ebola Virus
- the disclosed compounds inhibit Ebola VP40 protein.
- Ebola VP40 protein localizes to the inner leaflet of the plasma membrane of human cells where it provides an essential function in guiding the formation of new viral particles and is part of the viral particle.
- VP40's homodimer is a cytoplasmic protein that is an essential building block for the homo octomer formation (ring structure) in the early viral life cycle that regulates transcription and nuclear import; while a linear homo hexamer formation in the late viral life cycle regulates viral particle assembly at the inner plasma membrane of the cell.
- the disclosed compounds inhibit Ebola VP40 protein, thereby impairing the assembly of infectious viral particles of the Ebola virus. This results in keeping the Ebola virus from the formation of particles that can exit the host cell, thereby truncating the virulence of Ebola viruses.
- a method for inhibiting the self-assembly of Ebola VP40 protein in a cell comprising contacting a cell in vitro, ex vitro or in vivo that is infected with one or more Ebola viruses with one or more compounds of Formula (I).
- this method includes treatment of all mammals, especially treatment of humans.
- One embodiment of this aspect of the disclosure relates to methods for treating a subject having an Ebola virus infection, comprising contacting the subject with a therapeutically effective amount of one or more compounds of Formula II:
- One example of this embodiment comprises, contacting a subject having an Ebola virus infection with a therapeutically effective amount of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide (sangivamycin) having Formula IIIa:
- a further example of this embodiment comprises, contacting a subject having an Ebola virus infection with a therapeutically effective amount of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-hydrazinyl-N-hydroxy-7H-pyrrolo[2,3-d]pyrimidine-5-carboximidamide having Formula IIIb:
- SLM5 Sangivamycin-Like Molecule 5
- DTP NIH Developmental Therapeutics Program
- Another example of this embodiment comprises, contacting a subject having an Ebola virus infection with a therapeutically effective amount of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-hydrazinyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboximidhydrazide having Formula IIIc:
- SLM6 Stemmettin-Like Molecule 6
- DTP NIH Developmental Therapeutics Program
- a still further example of this embodiment comprises, contacting a subject having an Ebola virus infection with a therapeutically effective amount of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-hydrazinyl-7H-pyrrolo[2,3-d] pyrimidine-5-carboximidamide having Formula IIId:
- SLM7 Sangivamycin-Like Molecule 7
- DTP NIH Developmental Therapeutics Program
- a yet further example of this embodiment comprises, contacting a subject having an Ebola virus infection with a therapeutically effective amount of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbothioamide (thiosangivamycin) having Formula IIIe:
- a method for inhibiting in a subject infected with one or more Ebola viruses, the self-assembly of Ebola VP40 protein comprising contacting the infected subject with a therapeutically effective amount of a compound chosen from:
- RNA dependent RNA polymerase (interchangeably referred to herein as the L polymerase or the L protein).
- the Ebola virus activity is inhibited by inhibiting L protein (RNA polymerase) activity, which in turn inhibits viral genome replication and the production of the Ebola virus.
- This method comprises, contacting a subject infected with an Ebola virus with a therapeutically effective amount of one or more compounds having Formula I or a pharmaceutically acceptable salt thereof.
- One embodiment of the methods for inhibiting Ebola virus RNA polymerase in a subject infected with an Ebola virus comprises, contacting the subject with a therapeutically effective amount of one or more compounds of Formula II:
- One example of this embodiment comprises, contacting a subject having an Ebola virus infection with a therapeutically effective amount of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide (sangivamycin) having Formula IIIa:
- Another example of this embodiment comprises, contacting a subject having an Ebola virus infection with a therapeutically effective amount of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-hydrazinyl-N-hydroxy-7H-pyrrolo[2,3-d]pyrimidine-5-carboximidamide having Formula IIIb:
- a further example of this embodiment comprises, contacting a subject having an Ebola virus infection with a therapeutically effective amount of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-hydrazinyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboximidhydrazide having the Formula IIIc:
- a still further example of this embodiment comprises, contacting a subject having an Ebola virus infection with a therapeutically effective amount of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-hydrazinyl-7H-pyrrolo[2,3-d] pyrimidine-5-carboximidamide having Formula IIId:
- a yet further example of this embodiment comprises, contacting a subject having an Ebola virus infection with a therapeutically effective amount of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbothioamide (thiosangivamycin) having Formula IIIe:
- the disclosed compounds can be used to treat an Ebola virus by inhibiting the activity of RNA polymerase and for infected cells wherein the virus has replicated prior to treatment, inhibits the release of Ebola viruses from the infected cell by inhibiting VP40 self-assembly.
- the disclosed compounds serve as prodrugs which form an active pharmaceutical ingredient (API) once inside cells, tissues and following contact with the human body.
- API active pharmaceutical ingredient
- the disclosed compounds can form a triphosphate analog which when formed in the cell can bind to VP40 to prevent multimerization or be incorporated into the RNA by viral RNA-dependent RNA polymerases or DNA-dependent RNA polymerases or DNA-dependent DNA polymerases and thereby stop replication of the virus by preventing appropriate replication of the viral genetic material and prevent viral gene expression.
- one aspect of the disclosure comprises, contacting the subject with a therapeutically effective amount of one or more compounds having Formula II, as shown above, that are converted in vivo to the corresponding triphosphate having Formula V:
- This API and the corresponding triphosphates of the other disclosed compounds can be readily prepared by enzymatic methods known in the art for the preparation of adenosine triphosphate.
- disclosed herein is the use of the disclosed compounds for preventing VP40 protein self-assembly of Ebola viruses thereby eliminating the ability of the virus to form a viral capsid. Also disclosed herein is the use of the disclosed compounds to inhibit the activity of Ebola virus RNA polymerase thereby inhibiting the Ebola virus from replicating in an infected cell.
- compositions suitable for delivery of the disclosed compounds include aqueous-based compositions.
- the compositions can be delivered intramuscularly or intravenously.
- the amount of the disclosed compounds delivered to a subject in a single treatment (also referred to herein as a “bolus”) can be determined by the person providing the treatment. In general, amounts up to 50 mg/kg can be delivered in a single treatment whether IM or IV.
- the disclosed single dose compositions can comprise any amount of the disclosed compounds from about 0.5 mg/kg to about 50 mg/kg, for example, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11 mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg, 17 mg/kg, 18 mg/kg, 19 mg/kg, 20 mg/kg, 21 mg/kg, 22 mg/kg, 23 mg/kg, 24 mg/kg, 25 mg/kg, 26 mg/kg, 27 mg/kg, 28 mg/kg, 29 mg/kg, 30 mg/kg 31 mg/kg, 32 mg/kg, 33 mg/kg, 34 mg/kg, 35 mg/kg, 36 mg/kg, 37 mg/kg, 38 mg/kg, 39 mg/kg, 40 mg/kg, 41 mg/kg, 42 mg/kg, 43 mg/kg, 44 mg/kg, 45 mg/kg
- compositions useful for providing a medicament for inhibiting Ebola virus transmission can comprise from about 0.5 mg/kg to about 50 mg/kg of the subject's body mass. Therefore, a single dose of the disclosed compounds can range from about 0.5 mg/kg to about 50 mg/kg of the subject's body mass. In one embodiment, the amount of compound in a single dose is from about 1 mg/kg to about 25 mg/kg of the subject's body mass. In another embodiment, the amount of compound in a single dose is from about 10 mg/kg to about 25 mg/kg of the subject's body mass. In a further embodiment, the amount of compound in a single dose is from about 15 mg/kg to about 25 mg/kg of the subject's body mass.
- the amount of compound in a single dose is from about 1 mg/kg to about 10 mg/kg of the subject's body mass. In a still further embodiment, the amount of compound in a single dose is from about 5 mg/kg to about 20 mg/kg of the subject's body mass.
- compositions suitable for a single dose administration comprising:
- FIGS. 1 A- 1 D are micrographs depicting the EGFP fluorescence and Hoechst 33342 nuclear DNA stains of wild type Ebola virus and the L117R Ebola virus mutation.
- FIG. 1 A is an image depicting EGFP fluorescence from the VP40 protein tagged with EGFP of the VP40 dimer in wild type Ebola virus.
- FIG. 1 B is the corresponding Hoechst 33342 DNA stain.
- FIGS. 1 A and 1 B indicate the wild type virus can dimerized, hence, form the hexamers which led to the formation of the viral capsid.
- FIGS. 1 C and 1 D demonstrate that the L117R mutation prevents dimerization resulting in the inability of the mutated virus to form virus-like particles (VLPs) on the plasma membrane, i.e., the fluorescent rings around the edges of cells.
- VLPs virus-like particles
- 293T cells were plated at 10,000 cells/well in 384-well format and transfected with EGFP-V5-VP40. After 4 hours the cells were treated with a range of concentrations of compound (600-2.34 nM). 16 hours after drug was added fluorescence was read (ex. 485/em. 535) on a Biotek Synergy4 plate reader and cells were fixed in 4% paraformaldehyde with Hoechst 33342 and washed with PBS for imaging.
- FIG. 2 A- 2 J demonstrate that sangivamycin causes a shift in membrane associated VP40.
- FIG. 2 A depicts the EGFP fluorescence of VP40 from wild type Ebola virus that has been treated with 2.34 nM of sangivamycin.
- FIG. 2 B is the corresponding Hoechst 33342 DNA stain image.
- FIG. 2 C depicts the EGFP fluorescence of VP40 from wild type Ebola virus that has been treated with 9.38 nM of sangivamycin.
- FIG. 2 D is the corresponding Hoechst 33342 DNA stain image.
- FIG. 2 E depicts the EGFP fluorescence of VP40 in wild type Ebola virus that has been treated with 37.5 nM of sangivamycin.
- FIGS. 2 F is the corresponding Hoechst 33342 DNA stain image.
- FIGS. 2 A- 2 F indicate the wild type virus can dimerized, hence, form the hexamers which led to the formation of the viral capsid.
- FIGS. 2 G- 2 J show a shift in membrane association as depicted with the L117R mutation in FIG. 1 C at 150 nM ( FIG. 2 G ) and 600 nM ( FIG. 21 ), revealing that at concentrations above 37.5 nM sangivamycin prevents VLP formation in the cell.
- FIG. 3 depicts a series of bar graphs for samples labeled A-F.
- the compounds from A-F are as follows:
- bar graphs depict the dose-response of EGFP fluorescent signal in cells treated with a concentration range of compounds expressed as % of the solvent control signal. Reading each histogram from left to right the doses are, in decreasing concentration, 30 ⁇ M, 15 ⁇ M, 7.5 ⁇ M, 3.75 ⁇ M, 1.88 ⁇ M, 0.94 ⁇ M, and 0.46 ⁇ M respectively. All compounds revealed a dose-dependent reduction in EGFP fluorescence with Samples A, B and F showing the largest decrease in signal.
- FIG. 4 lanes 1, 2 and 3 represent 3, 6 and 12 ⁇ L of VLP isolated from wild type VP40 expressing cells.
- FIG. 4 lane 4 represents 12 ⁇ L of VLP isolated from L117R VP40 expressing cells. VLP were detected at the lowest amount loaded for wild type ( FIG. 4 lane 1), however, no signal was detected at the highest loading amount for L117R ( FIG. 4 lane 4) which cannot form VLP.
- FIG. 5 depicts VLP isolated from A) DMSO control, B) 5 nM sangivamycin, C) 50 nM sangivamycin, and D) 500 nM sangivamycin with lanes 1, 2 and 3 again showing 3, 6 and 12 ⁇ L of VLP.
- FIGS. 5 A and 5 B show similar amounts of VLP
- FIG. 5 C shows a clear reduction in VLP at 50 nM sangivamycin.
- FIG. 5 D shows a drastic reduction in VLP at 500 nM sangivamycin with VLP only faintly detected at 12 ⁇ L in lane 3.
- FIGS. 1 - 4 The data depicted in FIGS. 1 - 4 indicate that sangivamycin and its analogs affect the ability of VP40 to form VLP, in the absence of other Ebola components. Because sangivamycin is a nucleoside analog, minigenome assays were performed to test the effect sangivamycin has on Ebola's L polymerase (i.e. the typical target of antiviral nucleoside analogs).
- Table I summarizes a minigenome assay of sangivamycin and sangivamycin hydrochloride.
- a six plasmid minigenome expression system (GFP-7A editing site-mCherry, T7, NP, VP35, VP30, L) enables expression of both GFP and mCherry fluorescent reporters through the Ebola L polymerase requiring accessory viral proteins NP, VP35, VP30 for activity and T7 RNA polymerase to boost initial transcription.
- the results shown in Table I indicate that both GFP and mCherry expression were inhibited in the presence of 15 ⁇ M sangivamycin or sangivamycin HCl.
- FIG. 6 indicates that sangivamycin inhibits RNA transcription and replication through the Ebola L polymerase in minigenome reporter systems.
- the data found in FIG. 6 are from a similar minigenome assay. The difference was that the GFP-7A editing site-mCherry reporter was replaced with a luciferase reporter.
- a tetrazolium salt-based cell viability assay was used to measure the relative cytotoxicity ( ⁇ ).
- the tetrazolium compound was bio-reduced by cells to a colored formazan product by dehydrogenase enzymes in metabolically active cells thereby measuring cell viability.
- the data from Table I and FIG. 6 indicate sangivamycin affected both Ebola transcription through the L polymerase.
- FIGS. 7 A- 7 F are graphs summarizing cell-based antiviral assays.
- the percent inhibition that the test compounds displayed is indicated by ( ⁇ ), whereas the percent toxicity is indicated by ( ⁇ ).
- ⁇ percent inhibition that the test compounds displayed
- ⁇ percent toxicity
- FIG. 7 A corresponds to sangivamycin
- FIG. 7 B corresponds to sangivamycin HCl
- FIG. 7 C corresponds to the compound having Formula IIIb
- FIG. 7 D corresponds to the compound having Formula IIIc
- FIG. 7 E corresponds to the compound having Formula IIId
- FIG. 7 F corresponds to thiosangivamycin.
- FIG. 7 reveals that Ebola infectivity was inhibited by all analogs disclosed in FIG. 3 .
- the effect each compound had on VP40, as shown in FIG. 3 corresponds well to the levels shown in FIGS. 7 A- 7 F .
- These data indicate that sangivamycin and sangivamycin HCl had the greatest effect with IC 50 values of ⁇ 100 nM with the 50% cytotoxicity concentration not reached at the highest a concentration tested of 600 nM (dotted line on graphs represents the 50% IC or CC).
- the compounds represented by Formulae IIIb-IIId were less effective than sangivamycin and sangivamycin HCl.
- thiosangivamycin displayed nanomolar inhibitory concentrations in the Huh7 assay, the cytotoxicity and inhibitory concentrations overlapped, suggesting that in the Huh7 assay, the inhibitory activity could not be separated from thiosangimamycin's cytotoxic activity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
wherein X is chosen from O or S;
R1 is chosen from —NH2, —NHOH and —NHNH2; and
R2 is chosen from hydrogen and —NHNH2; or
a pharmaceutically acceptable salt thereof.
wherein X, R1 and R2 are the same as disclosed herein above; or
a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof. This compound is referred to in the literature as ‘Sangivamycin-Like Molecule 5 (SLM5) and is available from the NIH Developmental Therapeutics Program (DTP).
or a pharmaceutically acceptable salt thereof. This compound is referred to in the literature as ‘Sangivamycin-Like Molecule 6 (SLM6) and is available from the NIH Developmental Therapeutics Program (DTP).
or a pharmaceutically acceptable salt thereof. This compound is referred to in the literature as ‘Sangivamycin-Like Molecule 7 (SLM7) and is available from the NIH Developmental Therapeutics Program (DTP).
wherein X, R1 and R2 are the same as disclosed herein above; or
a pharmaceutically acceptable salt thereof.
This API and the corresponding triphosphates of the other disclosed compounds can be readily prepared by enzymatic methods known in the art for the preparation of adenosine triphosphate.
wherein X is chosen from O or S;
R1 is chosen from —NH2, —NHOH and —NHNH2; and
R2 is chosen from hydrogen and —NHNH2.
- A) 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide (sangivamycin) having Formula IIIa (NSC #65346);
- B) 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide (sangivamycin) hydrochloride, HCl salt of Formula IIIa (NSC #143648);
- C) 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-hydrazinyl-N-hydroxy-7H-pyrrolo[2,3-d]pyrimidine-5-carboximidamide having Formula IIIb (NSC #107517);
- D) 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-hydrazinyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboximidhydrazide having Formula IIIc (NSC #107512);
- E) 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-hydrazinyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboximidamide having Formula IIId (NSC #131663),
- F) 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbothioamide (thiosangivamycin) having Formula IIIe (NSC #105827).
TABLE I | ||||
Test Compound (15 μM) | % EGFP signal | % mCherry signal | ||
sangivamycin | 27 | 4 | ||
|
20 | 10 | ||
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/348,867 US11617753B2 (en) | 2016-11-10 | 2017-11-06 | Methods of treating and inhibiting Ebola virus infection |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662420474P | 2016-11-10 | 2016-11-10 | |
PCT/US2017/060207 WO2018089306A1 (en) | 2016-11-10 | 2017-11-06 | Methods of treating and inhibiting ebola virus infection |
US16/348,867 US11617753B2 (en) | 2016-11-10 | 2017-11-06 | Methods of treating and inhibiting Ebola virus infection |
Publications (2)
Publication Number | Publication Date |
---|---|
US20200188404A1 US20200188404A1 (en) | 2020-06-18 |
US11617753B2 true US11617753B2 (en) | 2023-04-04 |
Family
ID=62109317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/348,867 Active US11617753B2 (en) | 2016-11-10 | 2017-11-06 | Methods of treating and inhibiting Ebola virus infection |
Country Status (4)
Country | Link |
---|---|
US (1) | US11617753B2 (en) |
EP (1) | EP3538108A4 (en) |
CA (1) | CA3040540A1 (en) |
WO (1) | WO2018089306A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11779585B2 (en) | 2020-02-04 | 2023-10-10 | Oyagen, Inc. | Method for treating coronavirus infections |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3538108A4 (en) | 2016-11-10 | 2020-06-17 | Oyagen, Inc. | Methods of treating and inhibiting ebola virus infection |
WO2021211757A1 (en) * | 2020-04-14 | 2021-10-21 | Oyagen, Inc. | Method for treating arenaviridae infections |
Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3423398A (en) | 1965-05-10 | 1969-01-21 | Pfizer & Co C | Sangivamycin and derivatives thereof |
US6232282B1 (en) | 1997-10-10 | 2001-05-15 | The Procter & Gamble Company | Detergent composition containing mid-chain branched surfactants and an electrolyte for improved performance |
US6335339B1 (en) * | 1998-01-13 | 2002-01-01 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
WO2002057287A2 (en) | 2001-01-22 | 2002-07-25 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
US7442185B2 (en) | 2000-12-14 | 2008-10-28 | Shl Group Ab | Auto-injector |
WO2009067409A1 (en) | 2007-11-20 | 2009-05-28 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
US20100087388A1 (en) * | 2005-10-03 | 2010-04-08 | Kotra Lakshmi P | Odcase inhibitors as anti-virals and antibiotics |
US20100172917A1 (en) | 2003-07-22 | 2010-07-08 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
US20100233250A1 (en) | 2007-06-19 | 2010-09-16 | Benoit Baras | Vaccine |
US20110028564A1 (en) * | 2009-02-20 | 2011-02-03 | Johansen Lisa M | Compositions and methods for treatment of filovirus-mediated diseases |
US20110218210A1 (en) | 2007-11-02 | 2011-09-08 | Taiga Biotechnologies | Compounds for treating abnormal cellular proliferation |
US8038649B2 (en) | 2007-09-18 | 2011-10-18 | Shl Group Ab | Automatic injection device with needle insertion |
US8062255B2 (en) | 2006-12-13 | 2011-11-22 | Shl Group Ab | Auto-injector |
US8075517B2 (en) | 2008-06-11 | 2011-12-13 | Shl Group Ab | Medicament delivery device |
US20120014911A1 (en) | 2009-01-09 | 2012-01-19 | Serge Fuchs | Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor |
US8235952B2 (en) | 2007-03-23 | 2012-08-07 | Shl Group Ab | Auto injector |
US8277412B2 (en) | 2007-07-06 | 2012-10-02 | Shl Group Ab | One shot injector with dual springs |
US8440813B2 (en) | 2007-01-12 | 2013-05-14 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
US8529510B2 (en) | 2009-08-21 | 2013-09-10 | Shl Group Ab | Injection device |
US8551054B2 (en) | 2008-05-20 | 2013-10-08 | Shl Group Ab | Device for a medicament delivery device |
US20160122374A1 (en) | 2014-10-29 | 2016-05-05 | Gilead Sciences, Inc. | Methods for treating filoviridae virus infections |
US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
WO2018089306A1 (en) | 2016-11-10 | 2018-05-17 | Oyagen, Inc. | Methods of treating and inhibiting ebola virus infection |
WO2019018185A1 (en) | 2017-07-15 | 2019-01-24 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane derivatives for the treatment of filovirus infection |
WO2019079339A1 (en) | 2017-10-18 | 2019-04-25 | Avalon Flaviviral Therapeutics (Hk) Limited | Compositions and methods for broad-spectrum antiviral therapy |
US20190255085A1 (en) | 2015-09-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods for treating arenaviridae and coronaviridae virus infections |
US10479996B2 (en) | 2004-09-16 | 2019-11-19 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating ss/RNA viral infection |
US20190351048A1 (en) | 2016-12-23 | 2019-11-21 | Curevac Ag | Mers coronavirus vaccine |
US20200017514A1 (en) | 2018-07-12 | 2020-01-16 | Michael Plewe | Adamantane derivatives for the treatment of filovirus infection |
US10548971B2 (en) | 2013-11-29 | 2020-02-04 | The Trustees Of The University Of Pennsylvania | MERS-CoV vaccine |
US20210236497A1 (en) | 2020-02-04 | 2021-08-05 | Oyagen, Inc. | Method for treating coronavirus infections |
-
2017
- 2017-11-06 EP EP17869003.8A patent/EP3538108A4/en not_active Withdrawn
- 2017-11-06 US US16/348,867 patent/US11617753B2/en active Active
- 2017-11-06 WO PCT/US2017/060207 patent/WO2018089306A1/en unknown
- 2017-11-06 CA CA3040540A patent/CA3040540A1/en active Pending
Patent Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3423398A (en) | 1965-05-10 | 1969-01-21 | Pfizer & Co C | Sangivamycin and derivatives thereof |
US6232282B1 (en) | 1997-10-10 | 2001-05-15 | The Procter & Gamble Company | Detergent composition containing mid-chain branched surfactants and an electrolyte for improved performance |
US6335339B1 (en) * | 1998-01-13 | 2002-01-01 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
US7442185B2 (en) | 2000-12-14 | 2008-10-28 | Shl Group Ab | Auto-injector |
WO2002057287A2 (en) | 2001-01-22 | 2002-07-25 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
US7125855B2 (en) | 2001-01-22 | 2006-10-24 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
US20100172917A1 (en) | 2003-07-22 | 2010-07-08 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
US10479996B2 (en) | 2004-09-16 | 2019-11-19 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating ss/RNA viral infection |
US20100087388A1 (en) * | 2005-10-03 | 2010-04-08 | Kotra Lakshmi P | Odcase inhibitors as anti-virals and antibiotics |
US8062255B2 (en) | 2006-12-13 | 2011-11-22 | Shl Group Ab | Auto-injector |
US8440813B2 (en) | 2007-01-12 | 2013-05-14 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
US8235952B2 (en) | 2007-03-23 | 2012-08-07 | Shl Group Ab | Auto injector |
US20100233250A1 (en) | 2007-06-19 | 2010-09-16 | Benoit Baras | Vaccine |
US8277412B2 (en) | 2007-07-06 | 2012-10-02 | Shl Group Ab | One shot injector with dual springs |
US8038649B2 (en) | 2007-09-18 | 2011-10-18 | Shl Group Ab | Automatic injection device with needle insertion |
US20110218210A1 (en) | 2007-11-02 | 2011-09-08 | Taiga Biotechnologies | Compounds for treating abnormal cellular proliferation |
WO2009067409A1 (en) | 2007-11-20 | 2009-05-28 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
US8551054B2 (en) | 2008-05-20 | 2013-10-08 | Shl Group Ab | Device for a medicament delivery device |
US8075517B2 (en) | 2008-06-11 | 2011-12-13 | Shl Group Ab | Medicament delivery device |
US20120014911A1 (en) | 2009-01-09 | 2012-01-19 | Serge Fuchs | Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor |
US8475804B2 (en) | 2009-02-20 | 2013-07-02 | U.S. Army Medical Research And Material Command | Compositions and methods for treatment of filovirus-mediated diseases |
US20110028564A1 (en) * | 2009-02-20 | 2011-02-03 | Johansen Lisa M | Compositions and methods for treatment of filovirus-mediated diseases |
US8529510B2 (en) | 2009-08-21 | 2013-09-10 | Shl Group Ab | Injection device |
US10548971B2 (en) | 2013-11-29 | 2020-02-04 | The Trustees Of The University Of Pennsylvania | MERS-CoV vaccine |
US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
US20160361330A1 (en) | 2014-10-29 | 2016-12-15 | Gilead Sciences, Inc. | Methods for treating filoviridae virus infections |
US20190275063A1 (en) | 2014-10-29 | 2019-09-12 | Gilead Sciences, Inc. | Methods for treating filoviridae virus infections |
US9724360B2 (en) | 2014-10-29 | 2017-08-08 | Gilead Sciences, Inc. | Methods for treating Filoviridae virus infections |
US9949994B2 (en) | 2014-10-29 | 2018-04-24 | Gilead Sciences, Inc. | Methods for treating Filoviridae virus infections |
WO2016069826A1 (en) | 2014-10-29 | 2016-05-06 | Gilead Sciences, Inc. | Methods for treating filoviridae virus infections |
US20160122374A1 (en) | 2014-10-29 | 2016-05-05 | Gilead Sciences, Inc. | Methods for treating filoviridae virus infections |
WO2016069827A1 (en) | 2014-10-29 | 2016-05-06 | Gilead Sciences, Inc. | Methods for treating filoviridae virus infections |
US20190255085A1 (en) | 2015-09-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods for treating arenaviridae and coronaviridae virus infections |
WO2018089306A1 (en) | 2016-11-10 | 2018-05-17 | Oyagen, Inc. | Methods of treating and inhibiting ebola virus infection |
US20190351048A1 (en) | 2016-12-23 | 2019-11-21 | Curevac Ag | Mers coronavirus vaccine |
WO2019018185A1 (en) | 2017-07-15 | 2019-01-24 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane derivatives for the treatment of filovirus infection |
WO2019079339A1 (en) | 2017-10-18 | 2019-04-25 | Avalon Flaviviral Therapeutics (Hk) Limited | Compositions and methods for broad-spectrum antiviral therapy |
US20200017514A1 (en) | 2018-07-12 | 2020-01-16 | Michael Plewe | Adamantane derivatives for the treatment of filovirus infection |
US20210236497A1 (en) | 2020-02-04 | 2021-08-05 | Oyagen, Inc. | Method for treating coronavirus infections |
Non-Patent Citations (14)
Title |
---|
Cavins et al., "Initial toxicity study of sangivamycin (NSC-65346)," Cancer Chemotherapy Reports, 51(4):197-200 (1967). |
Corman et al., "Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR," Euro Surveillance, 25(30:2000045 (2020). |
Dolloff et al., "Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9," Molecular Cancer Therapies, 11(11)L:2321-2330 (2012). |
Dyall et al., "Discovery of Inhibitors of Middle East Respiratory Syndrome Coronavirus Infection" International Conference on Antimicrobial Research, Madrid Spain, Oct. 2014 (see abstract 41, p. 55). |
Hardesty et al., "The disposition of the antitumor agent, sangivamycin, in mice," Cancer Research, 34(5):005-1009 (1974). |
Hinshaw et. al., The J. Organic Chem., 1970, vol. 35(1), pp. 236-241 (Year: 1970). * |
Ji et al., "SARS-CoV proteins decrease levels and activity of human ENaC via activation of distinct PKC isoforms," American Journal of Physiology. Lung Cellular and Molecular Physiology, 296(3):L372-83 (2009). |
Krawczyk et. al., J. Med. Chem., 1995, vol. 38, pp. 4115-4119 (Year: 1995). * |
Kucic et al., "Inhibition of protein kinases C prevents murine cytomegalovirus replication," Journal of General Virology, 86(Pt 8):2153-2161 (2005). |
Panchal et. al., J. Biomolecular Screening, 2010, Soc. Laboratory Automation & Screening, vol. 15(7), pp. 755-765 (Year: 2010). * |
PubChem, "4-Amino-7-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-hydrazinylpyrrolo[2,3-d]pyrimidine-5-carboxamide," dated Nov. 9, 2021 (13 pages). |
U.S. Appl. No. 16/851,047, filed Apr. 16, 2020, Harold C. Smith. |
Vittori et al., "Antiviral properties of deazaadenine nucleoside derivatives," Current Medical Chemistry, 13(29):3529-3552 (2006). |
Wang et al., "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitrom," Cell Research, 30(3):269-271 (2020). |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11779585B2 (en) | 2020-02-04 | 2023-10-10 | Oyagen, Inc. | Method for treating coronavirus infections |
Also Published As
Publication number | Publication date |
---|---|
US20200188404A1 (en) | 2020-06-18 |
EP3538108A1 (en) | 2019-09-18 |
CA3040540A1 (en) | 2018-05-17 |
WO2018089306A1 (en) | 2018-05-17 |
EP3538108A4 (en) | 2020-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11617753B2 (en) | Methods of treating and inhibiting Ebola virus infection | |
JP5795714B2 (en) | Antiviral drugs for the treatment of arenavirus infections | |
EP3199181B1 (en) | Anti-influenza virus agent, and screening method for anti-influenza virus agent | |
Chu et al. | Paeoniflorin attenuates schistosomiasis japonica-associated liver fibrosis through inhibiting alternative activation of macrophages | |
DE60114772T2 (en) | AROMATIC GUANYLHYDRAZONE FOR THE TREATMENT OF RESISTANT VIRAL INFECTIONS | |
WO2013066748A1 (en) | Methods and compositions for treating hepatitis c virus | |
NZ754814A (en) | Method of treating intracellular infection | |
Xu et al. | Cardiac and muscle injury might partially contribute to elevated aminotransferases in COVID-19 patients | |
KR970007903B1 (en) | The pharmaceutical compositions for recovering transformed 2'-5'-oligo adenylate synthase (2',5')rna-asel natural preventire system | |
US20240093198A1 (en) | Tgf-beta therapeutics for age disease | |
CN1688316A (en) | Prophylaxis and treatment of infectious diseases | |
JP5326173B2 (en) | Drugs and screening methods for Epstein-Barr virus related diseases | |
CN110960533A (en) | Application of manidipine and temozolomide combined with medicine composition thereof in preparation of medicine for treating brain glioma | |
Ishii et al. | Effective ribavirin concentration in hamster brains for antiviral chemotherapy for subacute sclerosing panencephalitis | |
US20230241037A1 (en) | Cross-linked medication for treatment of coronaviral infection and method of treatment | |
JPWO2003035052A1 (en) | Virus infection prevention and treatment agent | |
US7482149B2 (en) | Inhibition of SARS coronavirus infection with clinically approved antiviral drugs | |
Nakasone et al. | Single oral administration of the novel CXCR4 antagonist, KRH-3955, induces an efficient and long-lasting increase of white blood cell count in normal macaques, and prevents CD4 depletion in SHIV-infected macaques: a preliminary study | |
US20090010880A1 (en) | 2-Amino-2,7-dideoxy-alpha-D-glycero-D-gluco-heptopyranosyl Inhibitors of Positive Sense Single-Stranded RNA Envelope Viruses | |
WO2013060980A1 (en) | Nucleoside analogues for treating a viral infection, and method for evaluating the sensitivity to said treatment | |
US20090298786A1 (en) | Methods of treating viral infections with anthracycline antibiotics | |
JP2020513232A (en) | Detection method of glucose metabolism abnormality and prevention and treatment | |
CN114903897B (en) | Application of stephanine in preparation of anti-tick-borne encephalitis virus medicament | |
JP2669937B2 (en) | Method for reversing resistance of HIV-1 strain to zidovudine | |
Nascimento et al. | Brief Introduction of Measles Virus and Its Therapeutic Strategies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: OYAGEN, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SMITH, HAROLD C.;BENNETT, RYAN P.;REEL/FRAME:052301/0926 Effective date: 20200330 Owner name: OYAGEN, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SMITH, HAROLD C.;BENNETT, RYAN P.;REEL/FRAME:052301/0920 Effective date: 20200330 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: EX PARTE QUAYLE ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO EX PARTE QUAYLE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JAHRLING, PETER BECKER;REEL/FRAME:063341/0168 Effective date: 20230411 |